Loading...
Header Logo
Keywords
Last Name
Institution

THERESE BARTHOLOMEW BEVERS

TitleProfessor
InstitutionMD Anderson
DepartmentClinical Cancer Prevention
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Brewster AM, Hawk E, Basen-Engquist K, Gilchrist SC. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One. 2019; 14(8):e0220814. PMID: 31369653.
      View in: PubMed
    2. Coletta AM, Brewster AM, Chen M, Li Y, Bevers TB, Basen-Engquist K, Gilchrist SC. High-Intensity Interval Training is Feasible in Women at High Risk for Breast Cancer. Med Sci Sports Exerc. 2019 Jun 20. PMID: 31269007.
      View in: PubMed
    3. Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila). 2019 Jul; 12(7):481-490. PMID: 31138522.
      View in: PubMed
    4. Phalak KA, Milton DR, Yang WT, Bevers TB, Dogan BE. Supplemental ultrasound screening in patients with a history of lobular neoplasia. Breast J. 2019 03; 25(2):250-256. PMID: 30675929.
      View in: PubMed
    5. Helvie MA, Bevers TB. Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position. J Natl Compr Canc Netw. 2018 Nov; 16(11):1398-1404. PMID: 30442738.
      View in: PubMed
    6. Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Nov; 16(11):1362-1389. PMID: 30442736.
      View in: PubMed
    7. Lowenstein LM, Escoto KH, Leal VB, Bailey L, Bevers TB, Cantor SB, Cinciripini PM, Jacobs LE, Esparza A, Godoy MC, Housten AJ, Lin H, Luckett P, Munden RF, Rabius V, Volk RJ. Randomized trial of a patient-centered decision aid for promoting informed decisions about lung cancer screening: Implementation of a PCORI study protocol and lessons learned. Contemp Clin Trials. 2018 09; 72:26-34. PMID: 30010085.
      View in: PubMed
    8. Housten AJ, Pappadis MR, Krishnan S, Weller SC, Giordano SH, Bevers TB, Volk RJ, Hoover DS. Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology. 2018 06; 27(6):1635-1641. PMID: 29575590.
      View in: PubMed
    9. Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA, Bevers T. A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ. Cancer Prev Res (Phila). 2018 05; 11(5):295-302. PMID: 29618460.
      View in: PubMed
    10. Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer. 2018 04; 17(2):287-294. PMID: 28988289.
      View in: PubMed
    11. Hoover DS, Pappadis MR, Housten AJ, Krishnan S, Weller SC, Giordano SH, Bevers TB, Goodwin JS, Volk RJ. Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women. Health Commun. 2019 Jun; 34(7):702-706. PMID: 29373069.
      View in: PubMed
    12. Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ. NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction. Cancer Prev Res (Phila). 2017 Nov; 10(11):625-634. PMID: 28978566.
      View in: PubMed
    13. Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C. Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. Patient Educ Couns. 2017 Dec; 100(12):2346-2354. PMID: 28734560.
      View in: PubMed
    14. Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL, Sneige N, Gong Y, Bevers TB. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Cancer Cytopathol. 2017 Aug; 125(8):644-651. PMID: 28498639.
      View in: PubMed
    15. Hovick SR, Bevers TB, Vidrine JI, Kim S, Dailey PM, Jones LA, Peterson SK. User Perceptions and Reactions to an Online Cancer Risk Assessment Tool: a Process Evaluation of Cancer Risk Check. J Cancer Educ. 2017 03; 32(1):141-147. PMID: 26546305.
      View in: PubMed
    16. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer. 2017 06 01; 123(11):1935-1940. PMID: 28135395.
      View in: PubMed
    17. Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT. Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. AJR Am J Roentgenol. 2017 Feb; 208(2):248-255. PMID: 27929664.
      View in: PubMed
    18. Austin A, Damani S, Bevers T. Clinical Approach for Patient-Centered Physical Activity Assessment and Interventions. Clin J Oncol Nurs. 2016 12 01; 20(6 Suppl):S2. PMID: 27857272.
      View in: PubMed
    19. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol. 2017 Jan; 24(1):70-76. PMID: 27573525.
      View in: PubMed
    20. Lowenstein LM, Richards VF, Leal VB, Housten AJ, Bevers TB, Cantor SB, Cinciripini PM, Cofta-Woerpel LM, Escoto KH, Godoy MC, Linder SK, Munden RF, Volk RJ. A brief measure of Smokers' knowledge of lung cancer screening with low-dose computed tomography. Prev Med Rep. 2016 Dec; 4:351-6. PMID: 27512650.
      View in: PubMed
    21. Bevers T, Bibbins-Domingo K, Oeffinger KC, Smith ML. Controversies in Breast Cancer Screening Strategies. J Natl Compr Canc Netw. 2016 05; 14(5 Suppl):651-3. PMID: 27226505.
      View in: PubMed
    22. Anderson BO, Bevers TB, Carlson RW. Clinical Breast Examination and Breast Cancer Screening Guideline. JAMA. 2016 Apr 05; 315(13):1403-4. PMID: 27046372.
      View in: PubMed
    23. Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66. PMID: 26797453.
      View in: PubMed
    24. Bradford A, Fellman B, Urbauer D, Bevers T. Effect of routine screening for sexual problems in a breast cancer survivorship clinic. Psychooncology. 2016 11; 25(11):1375-1378. PMID: 26449709.
      View in: PubMed
    25. Pruthi S, Heisey RE, Bevers TB. Chemoprevention for Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(10):3230-5. PMID: 26202562.
      View in: PubMed
    26. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):880-915. PMID: 26150582.
      View in: PubMed
    27. Bevers TB. Breast cancer risk reduction therapy: the low-hanging fruit. J Natl Compr Canc Netw. 2015 Apr; 13(4):376-8. PMID: 25870373.
      View in: PubMed
    28. Pruthi S, Heisey R, Bevers T. Personalized assessment and management of women at risk for breast cancer in North America. Womens Health (Lond). 2015 Mar; 11(2):213-23; quiz 223-4. PMID: 25776295.
      View in: PubMed
    29. Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient? JAMA. 2014 Sep 24; 312(12):1193-4. PMID: 25247511.
      View in: PubMed
    30. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun; 28(3):272-82. PMID: 24646362.
      View in: PubMed
    31. Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014 Jun; 3(3):492-9. PMID: 24639339.
      View in: PubMed
    32. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Prev Med. 2014 May; 62:60-3. PMID: 24518006.
      View in: PubMed
    33. Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR. Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study. Brain Imaging Behav. 2013 Dec; 7(4):533-42. PMID: 23955492.
      View in: PubMed
    34. Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomark Cancer. 2013; 5:71-80. PMID: 24324350.
      View in: PubMed
    35. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer. 2013 Dec; 13(6):439-49. PMID: 24119786.
      View in: PubMed
    36. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61. PMID: 23983047.
      View in: PubMed
    37. Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Cancer Cytopathol. 2013 Feb; 121(2):79-85. PMID: 23225501.
      View in: PubMed
    38. Mac Bride MB, Pruthi S, Bevers T. The evolution of breast self-examination to breast awareness. Breast J. 2012 Nov-Dec; 18(6):641-3. PMID: 23009674.
      View in: PubMed
    39. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: 22827973.
      View in: PubMed
    40. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol. 2012 May; 4(3):107-12. PMID: 22590484.
      View in: PubMed
    41. Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol. 2012 Feb; 198(2):W132-40. PMID: 22268202.
      View in: PubMed
    42. Reddy N, Ninan T, Tabar L, Bevers T. The results of a breast cancer screening cAMP at a district level in rural India. Asian Pac J Cancer Prev. 2012; 13(12):6067-72. PMID: 23464405.
      View in: PubMed
    43. Bevers TB. Breast cancer prevention: an update of the STAR trial. Curr Treat Options Oncol. 2010 Dec; 11(3-4):66-9. PMID: 21061192.
      View in: PubMed
    44. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010 Oct; 8(10):1112-46. PMID: 20971838.
      View in: PubMed
    45. Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S. A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. J Surg Oncol. 2010 Sep 01; 102(3):220-4. PMID: 20740578.
      View in: PubMed
    46. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010 Jun; 3(6):696-706. PMID: 20404000.
      View in: PubMed
    47. Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt). 2010 Mar; 19(3):371-9. PMID: 20136553.
      View in: PubMed
    48. Bevers TB. Alcohol and cancer incidence in women. Curr Oncol Rep. 2009 Nov; 11(6):417-20. PMID: 19840518.
      View in: PubMed
    49. Bevers TB. Breast awareness: a shift in the paradigm of breast self-examination. J Natl Compr Canc Netw. 2009 Nov; 7(10):1042-3. PMID: 19930973.
      View in: PubMed
    50. Cyrus-David M, King J, Bevers T, Robinson E. Validity assessment of the Breast Cancer Risk Reduction Health Belief scale. Cancer. 2009 Nov 01; 115(21):4907-16. PMID: 19637346.
      View in: PubMed
    51. Bevers TB, Anderson BO, Bonaccio E, Buys S, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T, Yaneeklov T. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009 Nov; 7(10):1060-96. PMID: 19930975.
      View in: PubMed
    52. Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol. 2009 Nov 01; 27(31):5144-52. PMID: 19770382.
      View in: PubMed
    53. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin. 2008 Nov-Dec; 58(6):347-71. PMID: 18981297.
      View in: PubMed
    54. Bevers TB. Ultrasound for the screening of breast cancer. Curr Oncol Rep. 2008 Nov; 10(6):527-8. PMID: 18928668.
      View in: PubMed
    55. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103. PMID: 18483331.
      View in: PubMed
    56. Bevers TB. CT screening for lung cancer. Curr Oncol Rep. 2007 Nov; 9(6):501-2. PMID: 17991359.
      View in: PubMed
    57. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007 Oct 11; 995. PMID: 18694095.
      View in: PubMed
    58. Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged
      View in: PubMed
    59. Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N. A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies. Acta Cytol. 2007 Sep-Oct; 51(5):749-54. PMID: 17910345.
      View in: PubMed
    60. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH. Breast cancer risk reduction. J Natl Compr Canc Netw. 2007 Sep; 5(8):676-701. PMID: 17927926.
      View in: PubMed
    61. Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw. 2007 Sep; 5(8):719-24. PMID: 17927929.
      View in: PubMed
    62. Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother. 2006 Nov; 7(16):2301-7. PMID: 17059385.
      View in: PubMed
    63. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat. 2007 May; 102(3):347-56. PMID: 17028980.
      View in: PubMed
    64. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21; 295(23):2727-41. PMID: 16754727.
      View in: PubMed
    65. Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C. Breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2006 May; 4(5):480-508. PMID: 16687096.
      View in: PubMed
    66. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16; 97(22):1652-62. PMID: 16288118.
      View in: PubMed
    67. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005 Oct 20; 23(30):7428-36. PMID: 16234510.
      View in: PubMed
    68. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005 Mar 15; 103(6):1122-8. PMID: 15712375.
      View in: PubMed
    69. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004 Aug 15; 92(6):1115-40. PMID: 15258897.
      View in: PubMed
    70. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res. 2002 Sep; 8(9):2835-42. PMID: 12231524.
      View in: PubMed
    71. Bevers TB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother. 2001 Nov; 55(9-10):559-64. PMID: 11769967.
      View in: PubMed
    72. Singletary E, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomarkers Prev. 2000 Oct; 9(10):1087-90. PMID: 11045792.
      View in: PubMed
    73. Controversies in breast cancer screening strategies. JNCCN Journal of the National Comprehensive Cancer Network. 14:651-653.
    74. Raloxifene. Expert Review of Obstetrics and Gynecology. 3:277-285.
    75. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention. Breast Diseases. 23:227-228.
    76. Development and evaluation of a decision aid on mammography screening for women 75 years and older. Breast Diseases. 25:313-315.
    77. Cyclical Mastalgia and Breast Cancer Risk. Breast Diseases. 18:30-31.
    78. 2-4 The Gail Model Predicts Breast Cancer in Women With Suspicious Radiographic Lesions. Breast Diseases. 17:136.
    79. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. Breast Diseases. 22:360-362.
    80. A brief measure of Smokers' knowledge of lung cancer screening with low-dose computed tomography. Preventive Medicine Reports. 4:351-356.
    81. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics.
    82. Quality of life in MAP.3 (mammary prevention 3). Breast Diseases. 26:123-124.
    83. Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer. Breast Diseases. 25:127-129.
    84. Are Primary Care Providers Prepared to Care for Survivors of Breast Cancer in the Safety Net?. Breast Diseases. 26:348-351.
    85. Green tea and risk of breast cancer in Asian Americans. Breast Diseases. 15:27.
    86. Guidelines challenge current practice and perceptions of breast cancer risk reduction therapy. Breast Diseases. 25:203-205.
    87. Diabetes and breast cancer risk. Breast Diseases. 24:139-140.
    88. Cancer Prevention, Screening, and Early Detection. 322-359.
    89. 1-6 Breast Cancer Risk Estimates for Relatives of White and African American Women With Breast Cancer in the Women's Contraceptive and Reproductive Experiences Study. Breast Diseases. 18:32.
    90. Volatile markers of breast cancer in the breath. Breast Diseases. 15:53.
    91. What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a US national survey. Breast Diseases. 16:25.
    92. Effect of routine screening for sexual problems in a breast cancer survivorship clinic. Psycho-Oncology.
    93. Raloxifene. Breast Diseases. 18:24-25.
    94. Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study. Breast Diseases. 24:324-326.
    95. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Breast Diseases. 22:178-180.
    96. Erratum. Women's Health. 12:390.
    97. Breast Cancer Risk Assessment and Prevention. Breast Diseases. 17:339.
    98. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Breast Diseases. 26:128-130.
    99. Clinical approach for patient-centered physical activity assessment and interventions. Clinical Journal of Oncology Nursing. 20:3-7.
    100. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer. Breast Diseases. 24:221-222.
    101. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Annals of Surgical Oncology. 1-7.
    102. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Breast Diseases. 16:142-143.
    103. Recruitment and retention challenges in breast cancer survivorship research. Breast Diseases. 15:122-123.
    104. Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention. Breast Diseases. 27:31-33.
    105. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Breast Diseases. 24:34-35.
    106. American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance Imaging. Seminars in Breast Disease. 11:111-112.
    107. User Perceptions and Reactions to an Online Cancer Risk Assessment Tool. Journal of Cancer Education.
    108. Screening for second primary cancers. 299-321.
    109. Erratum. Journal of Cellular Biochemistry. 93:427.
    110. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control. 27:359-366.
    111. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Breast Diseases. 23:195-196.
    112. Current Multidisciplinary Management of High-Risk Breast Lesions. Current Breast Cancer Reports. 7:81-89.
    113. Family history, mammographic density, and risk of breast cancer. Breast Diseases. 21:316.
    114. Chemoprevention for Breast Cancer. Annals of Surgical Oncology. 22:3230-3235.
    115. 2-5 The Influence of Family History on Breast Cancer Risk in Women With Biopsy-Confirmed Benign Breast Disease. Breast Diseases. 18:140-141.
    116. 1-2 Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women. Breast Diseases. 18:26-27.
    117. Association between uterine serous carcinoma and breast cancer. Breast Diseases. 16:28.
    118. A prospective study of diet and benign breast disease. Breast Diseases. 16:34-35.
    BEVERS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description